PMC 3827408
The clinical potential of this approach is underscored by the approval of istradefylline in Japan and the United States as an adjunct therapy for PD patients experiencing motor fluctuations, representing the most advanced A 2A receptor antagonists in clinical development [480482]
Common symptoms in LBD and FTD include delusion, hallucination, aggression, depression, anxiety, euphoria, apathy, disinhibition, appetite changes, and sleep disturbances (van de Beek et al., 2022
Despite longstanding interventions and guidelines, most countries remain off-track to meet global anaemia reduction targets, and recent cuts in global health funding further threaten progress
The first study to define astrocyte heterogeneity at single-cell resolution in MS and EAE